Silver Book Fact

Savings associated with t-PA treatment for ischemic stroke patients

A $600 net savings is associated with each ischemic stroke patient treated with t-PA. In 2005, only 2% of all ischemic stroke patients received t-PA. If that percentage was increased to 4% the realized cost savings would be approximately $15 million. If increased to 20%, the savings would be around $74 million.

Demaerschalk, BM and TR Yip. Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States. Stroke. 2005; 36(11): 2500-3. http://stroke.ahajournals.org/cgi/content/full/36/11/2500

Reference

Title
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Publication
Stroke
Publication Date
2005
Authors
Demaerschalk, BM and TR Yip
Volume & Issue
Volume 36, Issue 11
Pages
2500-3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cardiovascular disease mortality has declined by over 50% since 1950, contributing more than any other factor to the increase of life expectancy during the past few decades.  
  • Because of reduced mortality rates, the number of stroke survivors who are non-institutionalized increased from 2.0 to 2.4 million between 1980 and 1991.  
  • Beta-Blocker Treatment After A Heart Attack: Trends, 1996-2006  
  • Data from clinical trials demostrate that ICDs reduce sudden cardiac death 5-10% per year for 2-3 years, compared to antiarrhythmic drugs.  
  • Satisfaction rates of heart valve disease patients with their treatment